Last reviewed · How we verify
NAFT600 (pediatric)
NAFT600 is a botulinum toxin product used to reduce muscle contractions and treat movement disorders in pediatric patients.
NAFT600 is a topical antifungal agent that disrupts fungal cell membrane integrity by inhibiting ergosterol synthesis. Used for Tinea pedis (athlete's foot) in pediatric patients, Tinea cruris (jock itch) in pediatric patients, Tinea corporis (ringworm) in pediatric patients.
At a glance
| Generic name | NAFT600 (pediatric) |
|---|---|
| Also known as | NAFT600, naftifine, naftifine hydrochloride |
| Sponsor | Merz North America, Inc. |
| Drug class | Topical antifungal (allylamine) |
| Target | Squalene epoxidase (fungal) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Botulinum toxin works by blocking the release of acetylcholine at the neuromuscular junction, leading to temporary paralysis of targeted muscles. In pediatric applications, it is used to manage conditions characterized by abnormal muscle tone or involuntary movements. The effect is localized to injected muscles and is reversible over several months.
Approved indications
- Pediatric spasticity
- Pediatric movement disorders
Common side effects
- Injection site pain or bruising
- Muscle weakness
- Headache
- Flu-like symptoms
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NAFT600 (pediatric) CI brief — competitive landscape report
- NAFT600 (pediatric) updates RSS · CI watch RSS
- Merz North America, Inc. portfolio CI